Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-10-04
2005-10-04
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S958000, C536S023100, C536S023500, C536S023600, C536S023700, C536S025300, C435S069100, C435S440000, C435S455000
Reexamination Certificate
active
06951845
ABSTRACT:
The invention is directed to a method for treating both the early and late phases of allergic asthma by introducing naked polynucleotides which operatively encode for the asthma-initiating antigen into the host. The antigen-encoding polynucleotides are administered to host tissues which contain a high concentration of antigen presenting cells (e.g., skin and mucosa) relative to other host tissues. Expression of the asthma-initiating antigen encoding polynucleotides of the invention inside of antigen presenting cells (without substantial secretion therefrom) induces antigen tolerance while suppressing IgE antibody formation in the early phase of the disease, and also suppresses cytokine-mediated eosinophil accumulation in the late phase of the disease. Devices and compositions for use in the methods of the invention are also described.
REFERENCES:
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5985847 (1999-11-01), Carson et al.
patent: 6174872 (2001-01-01), Carson et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6426336 (2002-07-01), Carson et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6451320 (2002-09-01), Stephenne et al.
patent: 6498148 (2002-12-01), Raz
patent: 6514948 (2003-02-01), Raz et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6544518 (2003-04-01), Friede et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6562798 (2003-05-01), Schwartz
patent: 6610661 (2003-08-01), Carson et al.
patent: 2001/0044416 (2001-11-01), McCluskie et al.
patent: 2003/0026782 (2003-02-01), Krieg
patent: 2003/0050261 (2003-03-01), Krieg et al.
patent: 2003/0078223 (2003-04-01), Raz et al.
patent: 2003/0091599 (2003-05-01), Davis et al.
patent: 2003/0100527 (2003-05-01), Krieg et al.
patent: 2003/0133988 (2003-07-01), Fearon et al.
patent: 2003/0181406 (2003-09-01), Schetter et al.
patent: WO 90/11092 (1990-10-01), None
patent: WO 98/52962 (1998-11-01), None
Kandimalla et al, Current Opinion in Molecular Therapeutics, 2002, 4/2:122-129.
Kreig et al, Antisense and Nucleic Acid Drug Development, 1996, 6:133-139.
Uhlmann et al, Current Opinion in Drug Discovery and Development, 2003, 6/2:204-217.
Serebrisky et al, J. Immunology, 2000, 165:5906-5912.
Aderem et al, Cell, Dec. 2000, 103:993-996.
Kandimalla et al, Nucleic Acids Research, 2003, 31/9:2393-2400.
McCkuskie et al, Vaccine, 2001, 19:950-957.
Klinman et al, Vaccine, 1999, 17:19-25.
Mackay et al, New England J. Medicine, Jan. 11, 2001, 344/2:109-113.
Kreig et al, Nature, Apr. 6, 1995, 374:546-549.
Kreig et al, Trends in Microbiology, Jan. 1998, 6/1:23-27.
Klinman, Antisense and Nucleic Acid Drug Development, 1998, 8:181-184.
Roman et al, Nature Medicine, Aug. 1997, 3/8:849-854.
Horner et al, J. Allergy Clin. Immunol., 2002, 110:431-420.
Horner et al, J. Allergy Clin. Immunol., 2002, 110:706-712.
Peng et al, International Immunology, 2001, 13/1:3-11.
Broide et al, Springer Semin. Immunopathol., 2000, 22:117-124.
Van Uden et al, J. Allergy Clin. Immunol., 1999, 104:902-910.
Heeg et al, Int. Arch. Allergy Immunol., 2000, 121:87-97.
Magone et al, Eur. J. Immunol., 2000, 30:1841-1850.
Kline et al, Am. J. Physiol. Lung Cell Mol. Physiol., 2002, 283:L170-L179.
Tournaoy et al, Clin. Exp. All., 2002, 31:17-29.
Marshall et al, J. Allergy, Clin. Immunol., 2001, 108:191-197.
Broide et al, Int. Arch. Allergy Immunol., 1999, 118:453-456.
Hartmann et al, PNAS, USA, Aug. 1999, 96:9305-9310.
Kohama et al, J. Allergy Clin. Immunol., 1999, 104/6:1231-1238.
Broide et al, J. Immunology, 1998, 161:7054-7062.
Leonard et al, Biodrugs, 2003, 17/1:1-7.
Tighe et al, J. Allergy Clin. Immunol., 2000, 106:124-134.
Broide et al, In: Immunostimulatory DNA Sequences, Editor, Raz, 2001, pp. 117-124.
Klinman et al, Drug News Perspect, Jun. 2000, 13/5:289-297.
Yamamoto et al, In: Immunostimulatory DNA Sequences, Editor, Raz, 2001, pp. 11-19.
Kitagaki et al, In: Microbial DNA and Host Immunity, Editor, Raz, 2002, pp. 301-314.
Ikeda et al, In: Microbial DNA and Host Immunity, Editor, Raz, 2002, pp. 289-299.
Horner et al, In: Microbial DNA and Host Immunity, Editor, Raz, 2002, pp. 279-287.
Spiegelberg et al, Current Opinion in Molecular Therapeutics, 2002, 4/1:64-71.
Acsadi, et al. “Human dystrophin expression in mdx mice after intramusclular injection of DNA constructs”,Nature,(1991) vol. 352: 815-818.
Ballas, et al. “Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA”,Journal of Immunology,(1996) vol. 157: 1840-1845.
Barr, et al. “Systemic delivery of recombinant proteins by genetically modified myoblasts”,Science,(1991) vol. 254: 1507-1512.
Been, et al. “One binding site determines sequence specificity of tetrahymena Pre-rRNA self splicing, trans-splicing, and RNA enzyme activity”,Cell,(1986) vol. 47: 207-216.
Caligiuri, et al. “Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2”,J. Clin. Invest.,(1993) vol. 91: 123-132.
Chang, et al. “Nasal drug delivery”,Treatise on Controlled Drug Delivery,pp. 423-463.
Chien. “Mucosal drug delivery: Potential routes for noninvasive systemic administration”,Novel Drug Delivery Systems,vol. 50: 197-227.
Chien. “Transdermal drug delivery and delivery systems”,Novel Drug Delivery Systems,vol. 50: 301-380.
Chien. “Nasal drug delivery and delivery systems”,Novel Drug Delivery Systems,vol. 50: 229-268.
Chua, et al. “Sequence analysis of cDNA coding for a major house dust mite allergen”,J. Exp. Med.,(1988) vol. 167: 175-182.
Davis, et al. “Plasmed DNA Is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle”,Human Gene Therapy,(1993) vol. 4: 733-740.
Del Rey, et al. “Antidiabetic effects of interleukin 1”,Proc. Natl. Acad. Sci. USA,(1989) vol. 86: 5943-5947.
Donohue, et al. “In vivo administration of purified jurkat-derived interleukin 2 in mice”,Cancer Research,(1984) vol. 44: 1380-1386.
Goldstein, et al. “Repetitive weekly cycles of interleukin 2: Effect of outpatient treatment with a lower dose of interleukin 2 . . . ”,Cancer Research,(1989) vol. 49: 6832-6839.
Gorman, et al. “The rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells . . . ”,Proc. Natl. Acad. Sci. USA,(1982) vol. 79: 6777-6781.
Hefeneider, et al. “In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells”,Journal of Immunology,(1983) vol. 130(1): 222-227.
Hoyne, et al.Immunology and Cell Biology,(1986) vol. 74: 180-188.
Kaplan, et al. “Rational immunotheraphy with interleukin 2”,Bio/Technology,(1992) vol. 10: 157-162.
Kemeny, et al. “CD8+ T cells in allergy”,Allergy,(1992) vol. 47: 12-21.
Krieg, et al. “Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs”,Nucleic Acids Research, IRL Press Limited,(1984) vol. 12(18): 7057-7070.
Krieg, et al. “CpG motifs in bacterial DNA trigger direct B-cell activation”,Nature,(1995) vol. 374: 546-549.
Krieg, et al. “Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs”,Antisense and Nucleic Acid Drug Development,(1996) vol. 6: 133-139.
Kuramoto, et al. “Oligonucleotide sequences required for natural killer cell activation”
Carson Dennis A.
Raz Eyal
Borden Paula A.
Bozicevic Field & Francis LLP
Francis Carol L.
Minnifield Nita
The Regents of the University of California
LandOfFree
Method for treating allergic lung disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating allergic lung disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating allergic lung disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3475630